Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR and ONLY ADVR -- Ignore unavailable to you. Want to Upgrade?

To: KAKALAK who wrote (2)	9/22/2000 6:10:45 PM
From: Bernie Bildman	Read Replies (1) \| Respond to of 278

Hopefully we'll have others join in here, so that this doesn't degrade into a 2 way conversation between you and I (Ugh!). As far as what will help/hinder ADVR, your thoughts mimic mine (or vice versa - depending on who's been at this longer), the IND submission and (hopefully it acceptance) is the ONE determining factor that will permanently move this price. My observations include that the IND had better have fast track status, or I feel we may lose the race. Couple fast track acceptance with a partnership, and I can see the sky's the limit - from where I'm sitting (here in Alabama)! Many of your posts on RB continually note how many and how fast other companies are moving in the same direction that ADVR is. This IS a horse race, and I am hoping the company realizes this. ceoa+ has provided many poignant ideas about these issues that many there seem to discount. This IS more than a scientific project, this is a race for the SURVIVAL of this company. I truly believe in ADVR, and hopefully our trust and hopes will provide for investors a healthy return on out money and a drug for the health of many in the world.

To: KAKALAK who wrote (2)	9/22/2000 9:50:40 PM
From: KAKALAK	Respond to of 278

We are always working on financings to attract a group of investors in a private placement or equity line of credit at the best terms a bulletin board can attract. As you must be aware we get many solicitations of interest on deals and only select those which are most competitive, where we know the investors and their intentions. The company has just under $2 million and will pursue another financing before year end. We are not and have not postponed the IND filing for the benefit of any shareholder. IT is in the best interest of all shareholders and the company to file the IND as quickly as possible with the FDA. Regards, Alan Gallantar